A BILL 
To require reporting regarding certain drug price increases, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Fair Accountability 
4
and Innovative Research Drug Pricing Act of 2019’’ or 
5
the ‘‘FAIR Drug Pricing Act of 2019’’. 
6
01:26 Apr 23, 2019
H2296
2 
•HR 2296 IH
SEC. 2. REPORTING ON JUSTIFICATION FOR DRUG PRICE 
1
INCREASES. 
2
Title III of the Public Health Service Act (42 U.S.C. 
3
241 et seq.) is amended by adding at the end the fol-
4
lowing: 
5
‘‘PART W—DRUG PRICE REPORTING; DRUG 
6
VALUE FUND 
7
‘‘SEC. 399OO. REPORTING ON JUSTIFICATION FOR DRUG 
8
PRICE INCREASES. 
9
‘‘(a) DEFINITIONS.—In this section: 
10
‘‘(1) MANUFACTURER.—The term ‘manufac-
11
turer’ means the person— 
12
‘‘(A) that holds the application for a drug 
13
approved under section 505 of the Federal 
14
Food, Drug, and Cosmetic Act or the license 
15
issued under section 351 of the Public Health 
16
Service Act; or 
17
‘‘(B) who is responsible for setting the 
18
price for the drug. 
19
‘‘(2) QUALIFYING DRUG.—The term ‘qualifying 
20
drug’ means any drug that is approved under sub-
21
section (c) or (j) of section 505 of the Federal Food, 
22
Drug, and Cosmetic Act or licensed under subsection 
23
(a) or (k) of section 351 of this Act— 
24
‘‘(A) that has a wholesale acquisition cost 
25
of $100 or more per month supply or per a 
26
01:26 Apr 23, 2019
H2296
3 
•HR 2296 IH
course of treatment that lasts less than a 
1
month and is— 
2
‘‘(i)(I) subject to section 503(b)(1) of 
3
the Federal Food, Drug, and Cosmetic 
4
Act; or 
5
‘‘(II) commonly administered by hos-
6
pitals (as determined by the Secretary); 
7
‘‘(ii) not designated as a drug for a 
8
rare disease or condition under section 526 
9
of the Federal Food, Drug, and Cosmetic 
10
Act; and 
11
‘‘(iii) not designated by the Secretary 
12
as a vaccine; and 
13
‘‘(B) for which, during the previous cal-
14
endar year, at least 1 dollar of the total amount 
15
of sales were for individuals enrolled under the 
16
Medicare program under title XVIII of the So-
17
cial Security Act (42 U.S.C. 1395 et seq.) or 
18
under a State Medicaid plan under title XIX of 
19
such Act (42 U.S.C. 1396 et seq.) or under a 
20
waiver of such plan. 
21
‘‘(3) WHOLESALE
ACQUISITION
COST.—The 
22
term ‘wholesale acquisition cost’ has the meaning 
23
given that term in section 1847A(c)(6)(B) of the So-
24
cial Security Act (42 U.S.C. 1395w–3a(c)(6)(B)). 
25
01:26 Apr 23, 2019
H2296
4 
•HR 2296 IH
‘‘(b) REPORT.— 
1
‘‘(1) REPORT REQUIRED.—The manufacturer of 
2
a qualifying drug shall submit a report to the Sec-
3
retary for each price increase of a qualifying drug 
4
that will result in an increase in the wholesale acqui-
5
sition cost of that drug that is equal to— 
6
‘‘(A) 10 percent or more over a 12-month 
7
period; or 
8
‘‘(B) 25 percent or more over a 36-month 
9
period. 
10
‘‘(2) REPORT
DEADLINE.—Each report de-
11
scribed in paragraph (1) shall be submitted to the 
12
Secretary not later than 30 days prior to the 
13
planned effective date of such price increase. 
14
‘‘(c) CONTENTS.—A report under subsection (b) 
15
shall, at a minimum, include— 
16
‘‘(1) with respect to the qualifying drug— 
17
‘‘(A) the percentage by which the manufac-
18
turer will raise the wholesale acquisition cost of 
19
the drug on the planned effective date of such 
20
price increase; 
21
‘‘(B) a justification for, and description of, 
22
each manufacturer’s price increase that will 
23
occur during the 12-month period described in 
24
01:26 Apr 23, 2019
H2296
5 
•HR 2296 IH
subsection (b)(1)(A) or the 36-month period de-
1
scribed in subsection (b)(1)(B), as applicable; 
2
‘‘(C) the identity of the initial developer of 
3
the drug; 
4
‘‘(D) a description of the history of the 
5
manufacturer’s price increases for the drug 
6
since the approval of the application for the 
7
drug under section 505 of the Federal Food, 
8
Drug, and Cosmetic Act or the issuance of the 
9
license for the drug under section 351, or since 
10
the manufacturer acquired such approved appli-
11
cation or license; 
12
‘‘(E) the current list price of the drug; 
13
‘‘(F) the total expenditures of the manu-
14
facturer on— 
15
‘‘(i) materials and manufacturing for 
16
such drug; and 
17
‘‘(ii) acquiring patents and licensing 
18
for such drug; 
19
‘‘(G) the percentage of total expenditures 
20
of the manufacturer on research and develop-
21
ment for such drug that was derived from Fed-
22
eral funds; 
23
01:26 Apr 23, 2019
H2296
6 
•HR 2296 IH
‘‘(H) the total expenditures of the manu-
1
facturer on research and development for such 
2
drug that is used for— 
3
‘‘(i) basic and preclinical research; 
4
‘‘(ii) clinical research; 
5
‘‘(iii) new drug development; 
6
‘‘(iv) pursuing new or expanded indi-
7
cations for such drug through supple-
8
mental applications under section 505 of 
9
the Federal Food, Drug, and Cosmetic Act 
10
or section 351 of the Public Health Service 
11
Act; and 
12
‘‘(v) carrying out postmarket require-
13
ments related to such drug, including those 
14
under section 505(o)(3) of the Federal 
15
Food, Drug, and Cosmetic Act; 
16
‘‘(I) the total revenue and the net profit 
17
generated from the qualifying drug for each cal-
18
endar year since the approval of the application 
19
for the drug under section 505 of the Federal 
20
Food, Drug, and Cosmetic Act or the issuance 
21
of the license for the drug under section 351, 
22
or since the manufacturer acquired such ap-
23
proved application or license; and 
24
01:26 Apr 23, 2019
H2296
7 
•HR 2296 IH
‘‘(J) the total costs associated with mar-
1
keting and advertising for the qualifying drug; 
2
‘‘(2) with respect to the manufacturer— 
3
‘‘(A) the total revenue and the net profit 
4
of the manufacturer for each of the 12- and 36- 
5
month periods preceding the submission of the 
6
report; 
7
‘‘(B) all stock-based performance metrics 
8
used by the manufacturer to determine execu-
9
tive compensation for each of the 12- and 36- 
10
month periods preceding the submission of the 
11
report; and 
12
‘‘(C) any additional information the manu-
13
facturer chooses to provide related to drug pric-
14
ing decisions, such as total expenditures on— 
15
‘‘(i) drug research and development; 
16
or 
17
‘‘(ii) clinical trials on drugs that failed 
18
to receive approval by the Food and Drug 
19
Administration; and 
20
‘‘(3) such other related information as the Sec-
21
retary considers appropriate. 
22
‘‘(d) CIVIL PENALTY.—Any manufacturer of a quali-
23
fying drug that fails to submit a report for the drug as 
24
01:26 Apr 23, 2019
H2296
8 
•HR 2296 IH
required by this section shall be subject to a civil penalty 
1
of $100,000 for each day on which the violation continues. 
2
‘‘(e) PUBLIC POSTING.— 
3
‘‘(1) IN GENERAL.—Subject to paragraph (3), 
4
not later than 30 days after the submission of a re-
5
port under subsection (b), the Secretary shall post 
6
the report on the public website of the Department 
7
of Health and Human Services. 
8
‘‘(2) FORMAT.—In developing the format of 
9
such report for public posting, the Secretary shall 
10
consult stakeholders, including beneficiary groups, 
11
and shall seek feedback on the content and format 
12
from consumer advocates and readability experts to 
13
ensure such public reports are user-friendly to the 
14
public and are written in plain language that con-
15
sumers can readily understand. 
16
‘‘(3) TRADE SECRETS AND CONFIDENTIAL IN-
17
FORMATION.—In carrying out this section, the Sec-
18
retary shall enforce applicable law concerning the 
19
protection of confidential commercial information 
20
and trade secrets. 
21
‘‘SEC. 399OO–1. USE OF CIVIL PENALTY AMOUNTS. 
22
‘‘The Secretary shall, without further appropriation, 
23
collect civil penalties under section 399OO and use the 
24
funds derived from such civil penalties, in addition to any 
25
01:26 Apr 23, 2019
H2296
9 
•HR 2296 IH
other amounts available to the Secretary, to carry out ac-
1
tivities described in this part and to improve consumer and 
2
provider information about drug value and drug price 
3
transparency. 
4
‘‘SEC. 399OO–2. ANNUAL REPORT TO CONGRESS. 
5
‘‘(a) IN GENERAL.—Subject to subsection (b), the 
6
Secretary shall submit to Congress, and post on the public 
7
website of the Department of Health and Human Services 
8
in a way that is easy to use and understand, an annual 
9
report— 
10
‘‘(1) summarizing the information reported pur-
11
suant to section 399OO; and 
12
‘‘(2) including copies of the reports and sup-
13
porting detailed economic analyses submitted pursu-
14
ant to such section. 
15
‘‘(b) TRADE SECRETS AND CONFIDENTIAL INFORMA-
16
TION.—In carrying out this section, the Secretary shall 
17
enforce applicable law concerning the protection of con-
18
fidential commercial information and trade secrets.’’. 
19
Æ 
01:26 Apr 23, 2019
H2296
